Rennova Health (RNVA) Form 4 Rennova Health / Seamus Lagan ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lagan Seamus

(Last) (First) (Middle)

400 S. AUSTRALIAN AVE.,

SUITE 800

(Street)

WEST PALM BEACH, FL 33401

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rennova Health, Inc. [ RNVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series J Convertible Preferred Stock	$0.0017(1)	07/23/2018		A		250,000		07/23/2018	(5)	Common Stock	147,058,824(2)(3)	$1(4)	250,000	I	By: Alcimede LLC

1. Name and Address of Reporting Person^*

Lagan Seamus

(Last) (First) (Middle)

400 S. AUSTRALIAN AVE.,

SUITE 800

(Street)

WEST PALM BEACH, FL 33401

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Alcimede LLC

(Last) (First) (Middle)

400 S. AUSTRALIAN AVE.,

SUITE 800

(Street)

WEST PALM BEACH, FL 33401

(City) (State) (Zip)

Explanation of Responses:

1. As of July 23, 2018. The conversion price equals the average closing price of the common stock for the 10 trading days prior to the conversion date.

2. Based on the conversion price as of July 23, 2018.

3. Each share of the Series J Convertible Preferred Stock has the number of votes equal to the number of shares of common stock into which it is convertible, except that, for certain specified matters, through September 30, 2018 only each share has 12,000 votes.

4. Alcimede LLC received the shares in exchange for the cancellation of outstanding debt.

5. The Series J Preferred Stock will remain outstanding until either converted or redeemed by the Company.

Remarks:

Exhibit List - Exhibit 99 - Joint Filer Information

	/s/ Seamus Lagan	07/25/2018
	Alcimede LLC By: /s/ Seamus Lagan, Sole Manager	07/25/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.